第三届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：605369 证券简称：拱东医疗 公告编号：2025-008 浙江拱东医疗器械股份有限公司 浙江拱东医疗器械股份有限公司（以下简称"公司"）第三届董事会第十四 次会议于 2025 年 4 月 21 日在公司三楼会议室以现场结合通讯表决方式召开。会 议通知已于 2025 年 4 月 10 日通过专人、邮件送达及电话、微信通知等方式发出。 本次会议由董事长施慧勇先生主持，会议应出席董事 7 人，实际出席董事 7 人（其 中以通讯表决方式出席会议的董事 4 人）。公司监事、高级管理人员列席本次会 议。本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，决议内容合法有效。 二、董事会会议审议情况 （一）审议通过了《关于公司 2024 年年度报告及其摘要的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 公司董事会及全体董事保证年度报告内容的真实性、准确性、完整性，不存 在虚假记 ...

证券代码：605369 证券简称：拱东医疗 公告编号：2024-010 浙江拱东医疗器械股份有限公司 2024 年度利润分配及公积金转增股本方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 分配比例：向全体股东，每 10 股派发现金红利 4.00 元（含税），同时以 资本公积金每 10 股转增 4 股。 本次利润分配及资本公积金转增股本方案（以下简称"本方案"）以实施 权益分派股权登记日登记的总股本为基数，具体日期将在权益分派实施公告中明 确。 在实施权益分派的股权登记日前浙江拱东医疗器械股份有限公司（以下 简称"公司"）总股本发生变动的，拟维持每股分配比例不变，相应调整分配总 额。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下 简称"《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 本方案尚需提交公司股东大会审议。 一、利润分配方案内容 经天健会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司期末可 ...

Dividend and Share Repurchase - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares, totaling approximately 62.91 million CNY (including tax) based on a total share count of 157,578,415 shares[6]. - The total cash dividend for the year, including the interim dividend, amounts to approximately 109.81 million CNY, representing 84.95% of the net profit attributable to shareholders[7]. - The company intends to increase its share capital by 4 shares for every 10 shares held, resulting in a total share capital of approximately 220.49 million shares post-issuance[7]. - The company has repurchased shares worth approximately 35.99 million CNY during the year, which is considered part of the cash dividend calculation[6]. - The company has not engaged in any share repurchase and cancellation through tender offers or block trades during the year[7]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. Financial Performance - The company's operating revenue for 2024 reached CNY 111,520.95 million, representing a 14.37% increase compared to CNY 97,508.44 million in 2023[24]. - Net profit attributable to shareholders for 2024 was CNY 17,163.28 million, a significant increase of 57.28% from CNY 10,912.58 million in 2023[24]. - The basic earnings per share for 2024 was CNY 1.09, up 57.97% from CNY 0.69 in 2023[25]. - The weighted average return on equity increased to 10.16% in 2024, up by 3.45 percentage points from 6.71% in 2023[25]. - The net cash flow from operating activities for 2024 was CNY 21,037.93 million, reflecting a 13.48% increase from CNY 18,539.27 million in 2023[24]. - Total assets at the end of 2024 were CNY 195,134.02 million, a 3.92% increase from CNY 187,768.52 million at the end of 2023[24]. - The company reported a net asset attributable to shareholders of CNY 170,718.04 million at the end of 2024, which is a 4.19% increase from CNY 163,853.90 million at the end of 2023[24]. Market Strategy and Growth - The company plans to continue expanding its market presence and investing in new product development to drive future growth[34]. - Gongdong Medical's strategic focus includes expanding its global footprint and enhancing production capabilities through AI-driven flexible manufacturing lines[36]. - The company is actively upgrading its manufacturing capabilities with AI-driven automation to enhance production efficiency and product consistency[67]. - The company aims to enhance its management efficiency through digital transformation and organizational resilience, implementing smart ERP and MES systems[119]. - The company plans to deepen its global layout by establishing a triangular production network in North America, Europe, and Southeast Asia, enhancing collaboration with international clients[118]. Research and Development - R&D expenses totaled 53.05 million yuan, accounting for 4.76% of the revenue during the reporting period[37]. - The company has a strong focus on R&D, with a core team developing various advanced technologies related to disposable medical consumables[68]. - The company is exploring AI-assisted R&D in pharmaceutical packaging, particularly for emerging markets like ophthalmology and weight loss medications[124]. - The company is committed to building a long-term mechanism for innovation and talent development, collaborating with universities and clinical institutions[120]. Risk Management - The company has outlined potential risks in its future development, which investors are advised to review[10]. - The ongoing "collective procurement" policy poses significant risks, including pressure on the pricing structure and potential market exit of smaller manufacturers due to reduced profit margins[129]. - Future raw material price fluctuations could adversely affect the company's operating performance if not managed properly[130]. - The company faces risks from exchange rate fluctuations, which may impact export sales prices and overall performance due to the volatility of the RMB against the USD[130]. Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors[9]. - The company has not reported any product quality-related accidents, disputes, or litigation during the reporting period, but future uncertainties may pose risks[129]. - The company has not faced any penalties from securities regulatory authorities in the past three years[146]. - The company has established a comprehensive quality control system, with no reported incidents related to product quality during the reporting period[129]. Sustainability and Social Responsibility - The company invested 91.67 million yuan in environmental protection during the reporting period[181]. - The company has established an environmental management system and has been certified with ISO14001:2015 since June 2013[182]. - The company is committed to sustainable development and has adopted practices to conserve resources and reduce energy consumption[185]. - The company has a total donation of 310.50 million yuan for public welfare projects[187].

拱东医疗（605369）公告，2024年营业收入11.15亿元，同比增长14.37%。归属于上市公司股东的净利 润1.72亿元，同比增长57.28%。公司拟向全体股东每10股派发现金红利4元(含税)，以公积金转增股本方 式每10股转增4股。 ...

Core Insights - The company, Gongdong Medical, closed at 24.51 yuan, down 1.45%, with a rolling PE ratio of 23.80 times and a total market capitalization of 3.862 billion yuan [1] - The average PE ratio in the medical device industry is 44.77 times, with a median of 29.66 times, placing Gongdong Medical at the 59th position in the industry ranking [1] - As of the Q3 2024 report, 67 institutions hold shares in Gongdong Medical, with a total of 8.8357 million shares valued at 248 million yuan [1] Company Overview - Gongdong Medical specializes in the research, production, and sales of disposable medical consumables [1] - The main product categories include vacuum blood collection systems, laboratory testing consumables, bodily fluid collection consumables, medical care consumables, and pharmaceutical packaging materials [1] - The products are widely used in clinical diagnosis and care, scientific research testing, and pharmaceutical packaging [1] - The company has obtained ISO13485 quality management system certification and has 29 domestic medical device registrations or filings [1] - Some products have also received FDA510(k) product approval and EU CE certification, ensuring stable and reliable quality during mass production [1] Financial Performance - For Q3 2024, Gongdong Medical reported revenue of 836 million yuan, a year-on-year increase of 17.31% [2] - The net profit for the same period was 141 million yuan, reflecting a year-on-year growth of 60.22% [2] - The sales gross margin stood at 33.35% [2]

Core Viewpoint - The company, Zhejiang Gongdong Medical Instrument Co., Ltd., is experiencing growth in revenue and net profit, with a significant increase in both metrics year-on-year, indicating a strong performance in the medical device industry [1][2]. Company Summary - Gongdong Medical's stock closed at 24.97 yuan, up 1.13%, with a rolling PE ratio of 24.25 times and a total market capitalization of 3.935 billion yuan [1]. - The company specializes in the research, production, and sales of disposable medical consumables, including vacuum blood collection systems, laboratory testing consumables, bodily fluid collection consumables, medical care consumables, and pharmaceutical packaging materials [1]. - As of the third quarter of 2024, 67 institutions hold shares in Gongdong Medical, with a total of 8.8357 million shares valued at 248 million yuan [1]. Financial Performance - For the third quarter of 2024, Gongdong Medical reported an operating income of 836 million yuan, a year-on-year increase of 17.31%, and a net profit of 141 million yuan, reflecting a year-on-year growth of 60.22% [2]. - The company's gross profit margin stands at 33.35% [2]. Industry Context - The average PE ratio for the medical device industry is 46.15 times, with a median of 29.13 times, positioning Gongdong Medical at the 59th rank within the industry [1][2]. - The industry shows a wide range of PE ratios, with some companies exhibiting extremely high or negative values, indicating varying levels of performance and market perception [2].

在特朗普政府对全球贸易伙伴加征高关税的背景下，全球医疗供应链面临重构压力。近日，拱东医疗 （605369）在上证E互动平台回答投资者提问时表示，此次加征关税对公司影响较小，公司的美国子公 司TPI为客户提供多元化选择，可实现美国本土化生产，目前公司的客户遍布全球，主要客户均为全球 大型医疗或者生命科学领域的公司。 根据拱东医疗近期公布的2024年业绩预增公告，公司2024年度实现净利约1.75亿元，与上年同期相比， 增加约6587.42万元，同比增长约60.37%。 在全球医疗耗材市场竞争加剧的背景下，拱东医疗这一亮眼成绩的背后，是公司多年深耕海外市场、聚 焦大客户定制化战略的成果。据了解，近年来通过与McKesson、IDEXX、Medline等国际知名企业的长 期合作，拱东医疗产品销往全球100多个国家和地区。海外业务的快速增长不仅对冲了国内市场压力， 更成为公司业绩增长的核心引擎。 拱东医疗在业绩预增公告中表示，公司重点聚焦境外大客户定制业务，加强对全球体外诊断行业头部客 户的业务开拓力度，部分客户和项目进展顺利，大客户战略成效初步显现。 此外，拱东医疗通过收购美国子公司Trademark Plasti ...

当日关注点 公司公告汇总 拱东医疗发布关于第一期员工持股计划完成非交易过户的公告：- 浙江拱东医疗器械股份有限公司（证 券代码：605369，证券简称：拱东医疗）于2024年12月11日召开第三届董事会第十一次会议、第三届监 事会第七次会议，并于2024年12月27日召开2024年第三次临时股东大会，审议通过了关于公司第一期员 工持股计划的相关议案。- 根据实际认购情况及最终缴款审验结果，本员工持股计划参与认购首次受让 部分和预留受让部分（第一批次）份额的员工合计为79人，最终认购份额为14,632,128份，缴纳认购资 金总额为14,632,128.00元，认购份额对应股份数量为957,600股，股票来源为公司回购专用证券账户回购 的A股普通股股票。- 在实际认购过程中，部分拟参加对象因个人原因放弃认购，公司第一期员工持股 计划管理委员会第一次会议审议通过了调整首次受让部分拟分配份额及预留受让部分（第一批次）份额 分配的议案。- 2025年4月3日，公司收到中国证券登记结算有限责任公司出具的《过户登记确认书》， 确认957,600股公司股票已通过非交易过户方式过户至公司第一期员工持股计划账户。截至本公告披露 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605369 证券简称：拱东医疗 公告编号：2025-007 浙江拱东医疗器械股份有限公司 关于第一期员工持股计划完成非交易过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 浙江拱东医疗器械股份有限公司（以下简称"公司"）于2024年12月11日召开第三届董事会第十一次会 议、第三届监事会第七次会议，于2024年12月27日召开2024年第三次临时股东大会，审议通过了《关于 〈公司第一期员工持股计划（草案）〉及其摘要的议案》《关于〈公司第一期员工持股计划管理办法〉 的议案》等相关议案，同意公司实施第一期员工持股计划。具体内容敬请查阅公司2024年12月12日、 2024年12月28日披露于上海证券交易所网站（www.sse.com.cn）的相关公告。 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》及上海证券交易所《上市公司自律 监管指引第1号一一规范运作》的要求，现将公司第一期员工持股计划（以下简称"本员工持股计划"） 的实施进展情况公告如下： ...

浙江拱东医疗器械股份有限公司 证券代码：605369 证券简称：拱东医疗 公告编号：2025-007 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》及上海 证券交易所《上市公司自律监管指引第 1 号——规范运作》的要求，现将公司第 一期员工持股计划（以下简称"本员工持股计划"）的实施进展情况公告如下： 根据本员工持股计划首次受让部分和预留受让部分（第一批次）份额实际认 购情况及最终缴款的审验结果，本员工持股计划参与认购首次受让部分和预留受 让部分（第一批次）份额的员工合计为 79 人，最终认购份额为 14,632,128 份， 缴纳认购资金总额为 14,632,128.00 元，认购份额对应股份数量为 957,600 股，股 票来源为公司回购专用证券账户回购的公司 A 股普通股股票。 在实际认购过程中，鉴于本员工持股计划的部分拟参加对象因个人原因放弃 其拟认购的份额，持股计划人数发生变化，为保证本员工持股计划的顺利进行， 公司第一期员工持股计划管理委员会第一次会议审议通过了《关于调整公司第一 期员工持股计划首次受让部分拟分配份额的议案》《关于公司第一期员工持股计 划预留受让部分（第一批次）份额分 ...